Neonatal screening for Duchenne-type muscular dystrophy is greatly simplified by use of a new bioluminescence procedure for creatine kinase. The blood of newborn myopathic children consistently showed increased activity.
The improved method permits the analysis from a dried sample of whole blood spotted on filter paper; it shows high correlation with existing procedures and is highly specific and precise. The use of the improved method in a screening program involving 158 000 newborns is reviewed. We find a prevalence of 1/5929 living eighth-day boys.
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Duchenne-type muscular dystrophy (DMD),2 a severe xlinked pseudohypertrophic muscular dystrophy (1) , presents the following characteristics relevant to its diagnosis: a reported frequency of 1 in 5000 male newborns, a specific increase (50-to 200-fold) in serum CK (ATP:creatine N-phosphotransferase, EC 2.7.3.2) activity in the neonate, and later development of clinical symptoms (2, 3) . We report here the successful application of a new procedure for screening for DMD, which satisfies the criteria established for neonatal screening (5, 7) . Our specific objectives were (a) to study aspects of the methodology and (b) to determine the prevalence of DMD in our populations and the diagnostic sensitivity of the method. Two advantages of our method are the much smaller blood sample required and the fact that samples may be conveniently mailed to a centralized laboratory. The assay is based on the principle of reacting ATP, produced by CK, with firefly luciferase and photometrically recording the resulting light.
The coupled CK/luciferase reaction is specific for two reasons. First, ATP produced in the second step of the reaction depends only on the CK activity and the only biological phosphorylation catalyzed by CK is that of creatine (Nmethylglycocyamine).
N-Ethylglycocyamine and glycocyamine can also be acceptors or donators of phosphate groups, but these compounds are absent from biological media. Creatinine, arginine, histidine, and taurocyamine are inactive. Therefore, the amount of ATP produced after creatine phosphate is added depends only on the CK activity. Second, the light produced depends only on the luciferase reaction, The mixture is vortex-mixed and, during a 20-to 24-h preincubation in the dark at 12 to 18 #{176}C, the blood is eluted from the disk. The CK in the sample is reactivated by dithiothreitol, and luciferase (EC 2.8.2.10) consumes the pre-existing ATP (primarily erythrocytes) so that it cannot interfere with the CK assay. After this preincubation, 50 tL of Reagent B (100 mmol/L creatine phosphate in 50 mmol/L morpholinepropane sulfonic acid buffer, pH 7.3) is added to reaction mixture. The intensity of the light produced is proportional to the CK activity in the sample. We recorded it in terms of relative light units (RLU) in an Aminco photometer (cat. no. 4-7441).
Results

Sample stability.
Blood was sampled from five infants, all of whom had a myopathy but not all of whom had DMD. The test papers were stored at room temperature in the dark and analyzed one and 30 days after collection. Losses in activity (Table 1) were inappreciable in all cases, except for the highest-activity sample, which even after a month of storage would produce a positive result for DMD in this assay.
Reaction
specificity.
Reaction specificity was validated by
(a) ascertaining the activity of CK in Reagent A by use of blanks and (b) determining the CK activity in erythrocytes. In both cases, the results were essentially negative. Blanks were run by adding creatine phosphate to Reagent A under the test conditions described, except that washed erythrocytes were spotted on the test paper instead of whole blood. Under these conditions, no CK was detected. Further evidence for the lack of significant CX activity in erythrocytes was obtained as follows: cells from heparinized blood were washed five times with physiological saline, lysed, and diluted with an equal volume of a 70 g/L soKition of serum albumin. Four microliters of the lysed cell preparation was added to 200 sL of Reagent A, the mixture was preincubated for 20 h at 18 #{176}C, and, after the background light emission was determined (4 RLU), creatine phosphate was added and the light emission determined at 10 and 30 mm, with the sample at 18 #{176}C. The slight increase of light emission over blank values, noted at 10 mm, was too small to interfere substantially with the assay.
Precision. The overall precision of the test was determined for both liquid blood and dried blood spots. For the former, 
Correlation between methods.
Serum samples of unknown activity were diluted with an equal volume of saline-washed erythrocytes (type 0). One part of this reconstituted blood was applied to filter paper, for determination of CX with bioluminescence, while the serum was used for CX determination by a standard comparison procedure (8, 9) . The results (Table  3) demonstrate the good agreement between results by the two methods, consistent with the findings of Hwang and coworkers (15, 17) for porcine blood.
Discussion
Stability of the samples. In 1970, Bodensteiner and Zellweger (12) showed that the activity of CX in serum is quite stable when the blood is stored dry on a paper carrier. According to Dalal et al. (13) , CX in serum is subject to two types of inactivation: an irreversible inactivation, from which the CX is protected by the presence of albumin, and a reversible inactivation by oxidation of thiol groups.
Studies reported by Hwang (15) and our own personal experience show that storage at 25 #{176}C in the dark for 30 days results in a loss of not more than 25% of CX activity. 
Precision.
Obviously,poor reproducibility in punching out the small disks containing the dried blood is responsible for the high SDs we found. Nonetheless We found 12 cases of DMD. Of these, 10 showed values at least 15-fold the normal for adults. Among subjects whose values returned to the adult normal, some values were initially 70-fold normal (some cases of DMD reached 100 times the adult normal). Because of this overlap the diagnosis cannot be based solely on the result of the first screening test. Infants with above-normal values at birth are re-tested during the first well-baby visit, usually between 20 and 45 days. CX is measured in the serum at this time. The value for CK from infants with DM1) always exceeded 740 U/L, whereas a subject whose CX values have returned to normal never exceeded 480 UIL in the first well-baby visit (21). Our test results included no false negatives. The comparative efficiency of earlier detection of carriers is described elsewhere (21).
The methodology reported herein has been the subject of interesting applications outside of the usual area of postnatal muscular dystrophy screening. Wood CX assay may be a useful aid in identification of malignant hyperthermia in pigs (14, 17) and man (22) . Reagents A and B were used to determine CX isoenzymes in human muscle (23). Blood CX by the luciferase procedure was used for prenatal screening in a known carrier; the ultimate finding of low CX values resulted in the decision by the carrier mother not to seek an abortion and in the birth of a normal child (24). 
